M&T Bank
VRTX icon

M&T Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

M&T Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-200
Closed -$2K – 2249
2014
Q3 		$2K Buy
+200
New +$19K ﹤0.01% 2248

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

M&T Bank's VRTX Position: Q1 2026 in Review

M&T Bank reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, selling an estimated $767K and leaving 13,088 shares worth $5.84M. The position accounts for 0.02% of the portfolio, ranked #359.

M&T Bank first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.1M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • M&T Bank held 13,088 shares of Vertex Pharmaceuticals worth $5.84M as of Q1 2026.
  • M&T Bank sold 1,644 Vertex Pharmaceuticals shares in Q1 2026, an estimated $767K.
  • Vertex Pharmaceuticals made up 0.02% of M&T Bank's portfolio in Q1 2026, its #359 holding.
  • M&T Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • M&T Bank's Vertex Pharmaceuticals position peaked at $19.1M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.